Chow Chun Yuen

Dr. Chow Chun Yuen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KRKay L. Richards
Kay L. Richards
CMCarol J. Milligan
Carol J. Milligan
RRRobert J. Richardson
Robert J. Richardson
NJNikola Jancovski
Nikola Jancovski
MGMorten Grunnet
Morten Grunnet
SPSteven Petrou
Steven Petrou
Significance: Spider venom is a rich source of peptides, many targeting ion channels. We assessed a venom peptide, Hm1a, as a potential targeted therapy for Dravet syndrome, the genetic epilepsy linked to a mutation in the gene encoding the sodium channel alpha subunit Na V 1.1. Cell-based assays showed Hm1a was selective for hNa V 1.1 over other sodium and potassium channels. Utilizing a mouse model of Dravet syndrome, Hm1a restored inhibitory neuron function and significantly reduced seizures and mortality in heterozygote mice. Evidence from the structure of Hm1a and modeling suggest Hm1a interacts with Na V 1.1 inactivation domains, providing a structural correlate of the functional mechanisms. This proof-of-concept study provides a promising strategy for future drug development in genetic epilepsy and other neurogenetic disorders.

18 November 2020 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
DEDavid A. Eagles
David A. Eagles
CYChow Chun Yuen
Chow Chun Yuen
Glenn KingGlenn King
Glenn King

21 September 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
MRMeredith A. Redd
Meredith A. Redd
SSSarah E. Scheuer
Sarah E. Scheuer
NSNatalie J. Saez
Natalie J. Saez
YYYusuke Yoshikawa
Yusuke Yoshikawa
HCHan Sheng Chiu
Han Sheng Chiu
NPNathan J. Palpant
Nathan J. Palpant
Background: Ischemia–reperfusion injury (IRI) is one of the major risk factors implicated in morbidity and mortality associated with cardiovascular disease. During cardiac ischemia, the buildup of acidic metabolites results in decreased intracellular and extracellular pH, which can reach as low as 6.0 to 6.5. The resulting tissue acidosis exacerbates ischemic injury and significantly affects cardiac function. Methods: We used genetic and pharmacologic methods to investigate the role of acid-sensing ion channel 1a (ASIC1a) in cardiac IRI at the cellular and whole-organ level. Human induced pluripotent stem cell–derived cardiomyocytes as well as ex vivo and in vivo models of IRI were used to test the efficacy of ASIC1a inhibitors as pre- and postconditioning therapeutic agents. Results: Analysis of human complex trait genetics indicates that variants in the ASIC1 genetic locus are significantly associated with cardiac and cerebrovascular ischemic injuries. Using human induced pluripotent stem cell–derived cardiomyocytes in vitro and murine ex vivo heart models, we demonstrate that genetic ablation of ASIC1a improves cardiomyocyte viability after acute IRI. Therapeutic blockade of ASIC1a using specific and potent pharmacologic inhibitors recapitulates this cardioprotective effect. We used an in vivo model of myocardial infarction and 2 models of ex vivo donor heart procurement and storage as clinical models to show that ASIC1a inhibition improves post-IRI cardiac viability. Use of ASIC1a inhibitors as preconditioning or postconditioning agents provided equivalent cardioprotection to benchmark drugs, including the sodium-hydrogen exchange inhibitor zoniporide. At the cellular and whole organ level, we show that acute exposure to ASIC1a inhibitors has no effect on cardiac ion channels regulating baseline electromechanical coupling and physiologic performance. Conclusions: Our data provide compelling evidence for a novel pharmacologic strategy involving ASIC1a blockade as a cardioprotective therapy to improve the viability of hearts subjected to IRI.

1 June 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AAAkello J. Agwa
Akello J. Agwa
SPSteve Peigneur
Steve Peigneur
CYChow Chun Yuen
Chow Chun Yuen
NLNicole Lawrence
Nicole Lawrence
DCDavid J. Craik
David J. Craik
Christina I SchroederChristina I Schroeder
Christina I Schroeder
Gating modifier toxins (GMTs) are venom-derived peptides isolated from spiders and other venomous creatures that modulate activity of disease-relevant voltage-gated ion channels and are therefore being pursued as therapeutic leads. The amphipathic surface profile of GMTs has prompted the proposal that some GMTs simultaneously bind to the cell membrane and voltage-gated ion channels in a trimolecular complex. Here we examined whether there is a relationship among spider GMT amphipathicity, membrane binding and potency or selectivity for voltage-gated sodium (NaV) channels. We used NMR spectroscopy and in silico calculations to examine the structures and physicochemical properties of a panel of nine GMTs and deployed surface plasmon resonance to measure GMT affinity for lipids putatively found in proximity to NaV channels. Electrophysiology was used to quantify GMT activity on NaV1.7, an ion channel linked to chronic pain. Selectivity of the peptides was further examined against a panel of NaV channel subtypes. We show that GMTs adsorb to the outer leaflet of anionic lipid bilayers through electrostatic interactions. We did not observe a direct correlation between GMT amphipathicity and affinity for lipid bilayers. Furthermore, GMT–lipid bilayer interactions did not correlate with potency or selectivity for NaVs. We therefore propose that increased membrane binding is unlikely to improve subtype selectivity and that the conserved amphipathic GMT surface profile is an adaptation that facilitates simultaneous modulation of multiple NaVs.

1 November 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
CYChow Chun Yuen
Chow Chun Yuen
YCYanni K.Y. Chin
Yanni K.Y. Chin
LMLinlin Ma
Linlin Ma
EUEivind A.B. Undheim
Eivind A.B. Undheim
Volker HerzigVolker Herzig
Volker Herzig
Glenn KingGlenn King
Glenn King

30 June 2015 in Toxins
Verified
Journal Article
Open access
PDF file
CYChow Chun Yuen
Chow Chun Yuen
BCBen Cristofori-Armstrong
Ben Cristofori-Armstrong
EUEivind A. B. Undheim
Eivind A. B. Undheim
Glenn KingGlenn King
Glenn King
LRLachlan Rash
Lachlan Rash
Voltage-gated sodium (NaV) channels are responsible for propagating action potentials in excitable cells. NaV1.7 plays a crucial role in the human pain signalling pathway and it is an important therapeutic target for treatment of chronic pain. Numerous spider venom peptides have been shown to modulate the activity of NaV channels and these peptides represent a rich source of research tools and therapeutic lead molecules. The aim of this study was to determine the diversity of NaV1.7-active peptides in the venom of an Australian Phlogius sp. tarantula and to characterise their potency and subtype selectivity. We isolated three novel peptides, μ-TRTX-Phlo1a, -Phlo1b and -Phlo2a, that inhibit human NaV1.7 (hNaV1.7). Phlo1a and Phlo1b are 35-residue peptides that differ by one amino acid and belong in NaSpTx family 2. The partial sequence of Phlo2a revealed extensive similarity with ProTx-II from NaSpTx family 3. Phlo1a and Phlo1b inhibit hNaV1.7 with IC50 values of 459 and 360 nM, respectively, with only minor inhibitory activity on rat NaV1.2 and hNaV1.5. Although similarly potent at hNaV1.7 (IC50 333 nM), Phlo2a was less selective, as it also potently inhibited rNaV1.2 and hNaV1.5. All three peptides cause a depolarising shift in the voltage-dependence of hNaV1.7 activation.